Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 5/20 | 0.41 |
| ▸ | NMT2 | O60551 | 4/20 | 0.41 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.40 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.39 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.38 |
| ▸ | CALCR | P30988 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 4/20 | 0.38 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31468804 | 0.92 | NAA50 (0.36) | NMT1NMT2NMUR2NMUR1PLK1 | |
| SCHEMBL31257058 | 0.88 | PLK1 (0.40) | NMUR2NMUR1PLK1NAA50APLNR | |
| SCHEMBL7935083 | 0.87 | RAMP3 (0.46) | NMUR2NMUR1RAMP3CALCR | |
| SCHEMBL2790805 | 0.87 | CXCR4 (0.45) | NMUR2NMUR1RAMP3CALCR | |
| SCHEMBL10421719 | 0.87 | RAMP3 (0.46) | NMUR2NMUR1RAMP3CALCR | |
| SCHEMBL2790798 | 0.87 | CXCR4 (0.45) | NMUR2NMUR1RAMP3CALCR | |
| SCHEMBL12680175 | 0.87 | CXCR4 (0.45) | NMUR2NMUR1RAMP3CALCR | |
| SCHEMBL30918794 | 0.87 | APLNR (0.39) | NAA50RAMP3CALCRAPLNR | |
| SCHEMBL30905097 | 0.86 | OPRM1 (0.42) | NMUR2NMUR1ACE | |
| SCHEMBL30531335 | 0.86 | NMUR2 (0.42) | NMUR2NMUR1PLK1RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | NMT1 957/4885NMT2 1174/4885NMUR2 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.